Transdermal administration of morphine to the patients with pain

Transdermal administration of morphine to the patients with pain - Pharmacokinetic study of transdermal morphine

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000002027

Enrollment

Registered

2009-06-01

Start date

2009-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with pain

Interventions

Transdermal single administration of 30mg morphine Transdermal single administration of 60mg morphine Transdermal single administration of 90mg morphine Transdermal single administration of 180mg morp

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Cancer patients 2) Patients who have never treated with morphine 3) Patients who need opioid drugs including morphine

Exclusion criteria

Exclusion criteria: 1) Patients with severe respiratory disorder 2) Patients with bronchial asthma attack 3) Patients with severe liver dysfunction 4) Patients with heart failure associated with chronic lung disease 5) Patients with alcohol abuse 6) Patients susceptible with alkaloid

Design outcomes

Primary

Measure	Time frame
Pharmacokinetics of transdermal morphine	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026